Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions
Open Access
- 20 March 2026
- journal article
- review article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (3) , 169
Abstract
Acute myeloid leukemia (AML) is a molecularly heterogeneous neoplasm of hematopoietic stem and progenitor cells. The advent of high-resolution genomic sequencing has uncovered several genetic drivers of AML which spurred a surge of therapies that target the disease at a mutational, clonal, or epigenetic level. Currently, the molecular profiling of AML patients before treatment is commonplace and crucial for ensuring that patients receive the most optimal therapy for any driver mutations they may have. Here, we detail the current targeted therapies available for AML: specifically, those targeting the BCL2 family (venetoclax), FLT3 (midostaurin, gilteritinib, quizartinib), IDH1/2 (enasidenib, ivosidenib), and MENIN (revumenib, ziftomenib). In addition, we outline potential mechanisms of resistance against these therapies, as well as efforts being taken to prevent or bypass them.Keywords
Funding Information
- National Cancer Institute (P30 CA008748)
- Foundation for the National Institutes of Health (T32GM007739)
- Memorial Sloan Kettering Cancer Center Grayer Fellowship
- National Institutes of Health (1F30CA284575-01A1)
- ASH Graduate Hematology Award
This publication has 97 references indexed in Scilit:
- A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndromeJournal of Cancer Research and Clinical Oncology, 2022
- A review of FLT3 inhibitors in acute myeloid leukemiaBlood Reviews, 2022
- A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged LeukemiaCancer Cell, 2019
- Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemiaInvestigational New Drugs, 2017
- Transcriptional activation by MLL fusion proteins in leukemogenesisExperimental Hematology, 2017
- Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AMLCell, 2012
- The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated LeukemogenesisCell, 2005
- The homeodomain protein Meis1 is essential for definitive hematopoiesis and vascular patterning in the mouse embryoDevelopmental Biology, 2005
- Molecular cloning of a ligand for the flt3flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cellsCell, 1993
- A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populationsCell, 1991